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Indicator-speciﬁc effectObjective: The Pittsburgh Sleep Quality Index (PSQI) is used extensively to assess subjective sleep distur-
bance in cancer populations. Although previous studies on the PSQI suggested a better ﬁt for a two- or
three-factor model than the original one-factor model, none accounted for the indicator-speciﬁc effect
between sleep duration and habitual sleep efﬁciency. This study evaluated the PSQI’s dimensionality
and its convergent validity with cancer-related psychopathological states in female breast cancer
patients.
Methods: The PSQI was administered to 197 women with breast cancer. Conﬁrmatory factor analysis
examined the relative ﬁt of one-, two-, three-, and revised one-factor models. The PSQI’s convergent
validity was evaluated via bivariate correlations between the PSQI factor scores and measures of anxiety,
depression, fatigue, pain, and quality of life.
Results: Conﬁrmatory factor analyses showed an adequate ﬁt for the revised one-factor model with the
PSQI global score as the overall index of sleep disturbance. Although the revised one- and two-factor solu-
tions showed statistically equivalent model ﬁts, the one-factor model was selected due to utility reasons.
The severity of sleep dysfunction that the PSQI global score represented was positively correlated with
anxiety, depression, fatigue, pain, and reduced quality of life.
Conclusion: The results support the PSQI’s original unidimensional structure, demonstrating that the PSQI
global score is a valid and parsimonious measure for assessing and screening sleep dysfunction in cancer
patients.
 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Sleep disturbance is prevalent in cancer patients, with common
symptoms including long latency periods before falling asleep, fre-
quent nocturnal awakenings, and impaired sleep quality [1]. Sleep
deprivation has been associated with decreased physical and men-
tal well-being such as greater fatigue, pain, anxiety, depression,
and reduced quality of life [2–4]. The Pittsburgh Sleep Quality In-
dex (PSQI) is a widely used 19-item self-report instrument that as-
sesses sleep disturbances [5]. The PSQI determines respondents’
usual bed and wake times, the number of actual hours slept, time
taken to fall asleep, and asks other Likert-type questions. These
items are then used to assess seven clinical components of sleep
difﬁculty: subjective sleep quality, sleep latency, sleep duration,habitual sleep efﬁciency, sleep disturbances, sleep medication,
and daytime dysfunction.
Validation studies have shown that the PDQI has adequate psy-
chometric properties in terms of reliability, construct validity, and
concurrent validity in clinical populations such as depressed pa-
tients [6,7], insomniacs [8], and cancer patients [9–11]. According
to the developers of the PSQI [5], the scale allows researchers to
determine sleep dysfunction over a one-month period via the com-
putation of a simple, global score that reﬂects the severity of sleep
disturbance. Although the developers’ proposed a unidimensional
structure, studies assessing its factorial validity have had inconsis-
tent results. Some validation studies have indicated that the PSQI
might be better represented by a two- [9,10,12] or three-factor
[6,13,14] model, rather than the original one-factor structure.
Given the broad use of the PSQI as a sleep measure in clinical tri-
als and research among cancer patients, uncovering its underlying
factor structure is essential for a precise assessment of sleep distur-
bance. Although most validation studies favor a multidimensional
scoring system over a single global score, there is no consensus
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the intrinsic overlapping natures of the components of sleep dura-
tion and habitual sleep efﬁciency have largely been overlooked in
these studies. Sleep duration refers to the number of actual hours
slept, whereas habitual sleep efﬁciency indicates the ratio of the
number of actual hours slept to the total number of hours spent in
bed. As both components are derived from the same item, the two
components are expected to show an indicator-speciﬁc effect, in
which they will share a speciﬁc variance and will be more highly
correlated with each other than with other indicators [15]. To our
knowledge, existing psychometric studies on the PSQI have yet to
adjust for this indicator-speciﬁc effect in their analyses. Failure to
take this effect into account might produce imprecise representa-
tions of the underlying factor structure [16].
Our objective was to investigate the factor structure of the PSQI
using data from a sample of breast cancer patients over a three-
week interval. Three previously reported factor structures – the
one-, two-, and three-factor models – were evaluated through a
series of conﬁrmatory factor analyses (CFAs). In this study, an addi-
tional one-factor model with a residual covariance between sleep
duration and habitual sleep efﬁciency was speciﬁed. The factor
models were compared according to their relative model ﬁt [17].
It would be theoretically meaningful to evaluate whether PSQI
factor scores offer an incremental value beyond the global score.
The convergent validity of the PSQI factor models was examined
by exploring the associations between the PSQI factor scores and
observed measures on cancer-related psychopathological states,
namely, anxiety, depression, fatigue, pain, and quality of life. A
moderate degree of association between PSQI factor scores and
the psychopathological states was expected.
2. Methods
2.1. Participants
This study evaluated the psychometric properties of the PSQI
through a secondary data analysis of a clinical trial of dance/move-
ment therapy for cancer treatment-related symptoms. Participants
of this study were recruited from three community cancer support
centres in Hong Kong using a prospective and consecutive sam-
pling design. Breast cancer patients, who were able to understand,
read, and write Chinese and were in Stage I, II or III of the disease,
were identiﬁed and invited to join the study via mail. The invita-
tion letter clearly stated the purpose and procedures of the study
and the potential beneﬁts and risks. A total of 197 female breast
cancer patients participated in the study and attended a brieﬁng
session where details of the study were delivered and informed
consent and baseline data were solicited. The participants were in-
volved in the dance/movement programme, which was a form of
palliative treatment for cancer treatment-related symptoms. The
participants had a mean age of 49.4 years (SD: 8.0) and an average
time since diagnosis of 23.2 months (SD: 7.5). More than half of the
sample were married (64.5%) and had had primary or secondary
education (65.5%). The majority of the participants had received
lumpectomy (56.4%) and chemotherapy (78.1%) and was undergo-
ing adjuvant radiotherapy treatment (70.1%). The questionnaire
data on anxiety, depression, sleep quality, fatigue, pain, and quality
of life were obtained from the participants at baseline (Time 1). A
subsample of 184 participants completed a follow-up assessment
three weeks later (Time 2). All of the procedures were approved
by the institutional review board of The University of Hong Kong.
2.2. Measures
The Chinese Pittsburgh Sleep Quality Index is a 19-item self-re-
port instrument for assessing sleep disturbance over the monthbefore questionnaire administration [5,12]. Seven component
scores – subjective sleep quality, sleep latency, sleep duration,
habitual sleep efﬁciency, sleep disturbances, sleep medication,
and daytime dysfunction – are computed from the items. The
scores for these components range from 0 (no difﬁculty) to 3
(severe difﬁculty) and are summed to produce a global measure
of sleep disturbance, with a higher score denoting poorer sleep
quality (range: 0–21). Previous validation studies [11,18] have sug-
gested a cut-off of the global score atP8 for the presence of sleep
disturbance in cancer patients. In the present study, the PSQI had a
Cronbach’s a of 0.79 at both Times 1 and 2, indicating acceptable
levels of reliability. The PSQI displayed good test–retest reliability
(r = 0.79, P < 0.01) over the three-week interval.
Anxiety and depression were measured using the Chinese Hos-
pital Anxiety and Depression Scale [19]. This is a 14-item instru-
ment that assesses the severity of anxiety and depressive
symptoms using a four-point response format. The total score for
anxiety (seven items) and depression (seven items) combined
ranges from 0 to 21, with a higher score denoting worse status.
In the present study, the Cronbach’s a was 0.85 for anxiety and
0.82 for depression at both Times 1 and 2. The Brief Fatigue Inven-
tory [20] was used to assess fatigue symptoms. This is a nine-item
instrument that measures the severity and interference of fatigue
symptoms using an 11-point response format. The average score
of the nine items is used as the total scale score, with a higher score
denoting greater fatigue. In our study, the Cronbach’s a for the
scale was 0.95 at Time 1 and 0.96 at Time 2.
The Brief Pain Inventory [21] was used to assess the pain symp-
toms. This is an 11-item instrument that measures the severity and
interference of the pain symptoms using an 11-point response for-
mat. The total score for pain severity (four items) and pain interfer-
ence (seven items) ranges from 0 to 10, with a higher score
denoting worse status. In our study, the Cronbach’s a was 0.96
for pain severity and 0.95 for pain interference at both Times 1
and 2. Quality of life was assessed using the Functional Assessment
of Cancer Therapy – Breast scale [22]. This is a 36-item instrument
that measures quality of life in breast cancer patients in physical,
social, emotional, functional, and breast cancer speciﬁc domains
using a ﬁve-point format. The total score for quality of life ranges
from 0 to 144, with a higher score denoting a better quality of life.
In our study, the Cronbach’s a for the scale was 0.91 at Time 1 and
0.97 at Time 2.
2.3. Statistical analyses
Preliminary analysis of the attrition rate showed that the drop-
outs (n = 13) and non-dropouts (n = 184) did not differ signiﬁcantly
on any of the demographic characteristics or PSQI component
scores at baseline. A CFA was performed in Mplus version 7.11
[23] on the seven PSQI component scores using the robust maxi-
mum likelihood estimator. Missing data for PSQI item responses
were minimal, with no more than 2.5% of the data missing for
any component scores at Time 1 and Time 2. Therefore, missing
data were handled with full information maximum likelihood un-
der the missing at random assumption [24].
Four CFA models were speciﬁed for Time 1 and Time 2 data: the
original one-factor model [5], a two-factor model [12], a three-fac-
tor model [6], and a revised one-factor model. The one-factor mod-
el speciﬁed all of the seven components as indicators of a single
factor of sleep disturbance. In the two-factor model, the compo-
nents of subjective sleep quality, sleep latency, sleep medication,
sleep disturbances, and daytime dysfunction were reﬂective indi-
cators of the sleep quality factor, whereas sleep duration and habit-
ual sleep efﬁciency were reﬂective indicators of the sleep efﬁciency
factor. In the three-factor model, the components of subjective
sleep quality, sleep latency, and sleep medication were reﬂective
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turbances and daytime dysfunction were indicators of the daily
disturbances factor; and the components of sleep duration and
habitual sleep efﬁciency were indicators of the sleep efﬁciency fac-
tor. The revised one-factor model included a residual covariance
for sleep duration and habitual sleep efﬁciency. All four models
speciﬁed that each component should load on one factor only.
The model ﬁt was assessed based on the following criteria on
the ﬁt indices [25]: insigniﬁcant v2-test statistic; comparative ﬁt
index (CFI) P0.95; Tucker–Lewis index (TLI) P0.95; root mean
square error of approximation (RMSEA) 60.06; and standardized
root mean square residual (SRMR) 60.08. The model selection
was based on the v2-test statistic, Bayesian information criterion
(BIC), and theoretical considerations. The BIC takes model parsi-
mony into account by imposing penalties on the number of free
parameters estimated and adjustments for sample size [26]. A low-
er BIC indicates a better ﬁt with greater model parsimony.
The convergent validity of the PSQI was examined through
bivariate correlation analyses of the PSQI factor scores and six
observed scores on anxiety, depression, fatigue, pain severity, pain
interference, and quality of life. The PSQI factor scores were
derived from the best-ﬁtting factor model, as suggested by the
CFA results. For instance, the sum of all of the PSQI component
scores composed the standard PSQI global score. The statistical sig-
niﬁcance level was set at 0.05. To account for the inﬂation of type I
error due to multiple comparisons, Bonferroni adjustment was
made to control the overall type I error rate at 0.05 by multiplying
each P-value by a factor of six [27].3. Results
3.1. Descriptive statistics
The PSQI global score had a mean of 7.59 (SD: 4.12) at Time 1
and 7.38 (SD: 4.15) at Time 2. Using the cut-off PSQI score of P8,
46.0% and 39.5% of the participants reported sleep problems at
Time 1 and Time 2, respectively. Table 1 presents the mean scores,
SDs, and intercorrelations for the seven PSQI components at Time 1
and Time 2, separately. At Time 1, the mean component scores ran-
ged from the lowest, 0.37 for the sleep medication, to the highest,
1.65 for sleep latency. At Time 2, the mean component scores ran-
ged from the lowest, 0.28 for the sleep medication, to the highest,
1.56 for sleep disturbances. Although most of the correlations
among the seven components were moderate (r = 0.25–0.53), sleep
medications had weaker correlations with the other components
(r = 0.14–0.32). A notable exception was the expected strong corre-
lation between sleep duration and habitual sleep efﬁciency
(r = 0.76 at Time 1 and 0.78 at Time 2).Table 1
Descriptive statistics of PSQI components at Time 1 and Time 2.
1 2 3 4 5 6 7
1. Subjective sleep quality 0.53 0.53 0.52 0.49 0.27 0.47
2. Sleep latency 0.42 0.32 0.38 0.39 0.14 0.31
3. Sleep duration 0.45 0.30 0.76 0.33 0.30 0.27
4. Habitual sleep efﬁciency 0.47 0.41 0.78 0.34 0.30 0.25
5. Sleep disturbances 0.49 0.30 0.30 0.34 0.19 0.46
6. Sleep medications 0.23 0.19 0.16 0.15 0.24 0.29
7. Daytime dysfunction 0.49 0.32 0.27 0.25 0.49 0.32
Time 1 mean 1.36 1.65 0.76 1.03 1.50 0.37 1.00
Time 1 SD 0.75 0.91 0.95 1.13 0.59 0.88 0.88
Time 2 mean 1.33 1.54 0.75 1.06 1.56 0.28 0.96
Time 2 SD 0.78 0.93 1.00 1.14 0.61 0.84 0.86
PSQI, Pittsburgh Sleep Quality Index.
Correlations for Time 1 (n = 197) and Time 2 (n = 184) are displayed on the upper
and lower diagonals. All correlations are statistically signiﬁcant (P < 0.05).3.2. Factorial validity
Table 2 presents the goodness-of-ﬁt indices for the one-, two-,
three-, and revised one-factor models of the PSQI at Times 1 and
2. The one-factor model provided a poor ﬁt to the data at Times
1 and 2 (signiﬁcant v2: CFI <0.80, TLI <0.70, RMSEA >0.15). The re-
vised one-factor model provided an adequate ﬁt to the data at
Times 1 and 2 (insigniﬁcant v2: CFI and TLI >0.95; RMSEA and
SRMR <0.06). The revised one-factor model provided a signiﬁcantly
better ﬁt than the original one-factor model in terms of v2 differ-
ence and a substantially smaller BIC. The residual correlation be-
tween sleep duration and habitual sleep efﬁciency was strong
(r = 0.63 at Time 1; 0.70 at Time 2; P < 0.05). The standardized
parameter estimates for the revised one-factor model are displayed
in Fig. 1. The factor loadings were statistically signiﬁcant and ran-
ged from 0.36 (sleep medication) to 0.84 (subjective sleep quality).
The two-factor model produced a model ﬁt equivalent to the
revised one-factor model. The correlation between the sleep qual-
ity factor and sleep efﬁciency factor was 0.69 at Time 1 and 0.60 at
Time 2. The three-factor model produced a good model ﬁt to the
data at Time 1 and Time 2 (insigniﬁcant v2: CFI and TLI >0.99;
RMSEA and SRMR <0.04) and provided a signiﬁcantly smaller v2-
statistic than the other models. Nevertheless, the sleep quality
factor and daily disturbance factor exhibited an extremely high
correlation in this model (r = 0.85 at Time 1; r = 0.93 at Time 2),
indicating that these two factors were not well distinguished. This
unacceptable discriminant validity together with the higher BIC
suggested the possibility of overﬁtting and model redundancy.3.3. Convergent validity
Table 3 presents the correlations between the PSQI factor scores
and validating measures at Times 1 and 2. The PSQI global score
was positively correlated with anxiety, depression, fatigue, pain
severity, and pain interference (r = 0.31–0.50 at Time 1; r = 0.35–
0.53 at Time 2; P < 0.05), and negatively associated with quality
of life (r = 0.54 at Time 1; r = 0.57 at Time 2; P < 0.05). The sleep
quality factor showed similar correlations with anxiety, depres-
sion, fatigue, pain severity, pain interference (r = 0.36–0.55 at Time
1; r = 0.40–0.58 at Time 2; P < 0.05) and quality of life (r = 0.58 at
Time 1; r = 0.59 at Time 2; P < 0.05). However, the sleep efﬁciency
factor was not signiﬁcantly correlated with fatigue and pain sever-
ity (r = 0.13–0.16 at Time 1; r = 0.17–0.20 at Time 2; P > 0.05). It
had substantially smaller correlations with anxiety, depression,
pain interference, and quality of life than the PSQI global score.4. Discussion
This study examined various PSQI factor structures in a sample
of breast cancer patients, where the relative ﬁt of the one-, two-,
and three-factor models was compared. The three-factor model
[6] provided a good ﬁt to the data. However, an extraordinarily
strong correlation (r = 0.93) was found between the sleep quality
and daily disturbance factors. This ﬁnding is in line with previous
factor analytic results [6,12,14] and points to the model’s poor dis-
criminant validity. In addition, the high BIC of the three-factor
model compared to the two-factor model, despite its signiﬁcantly
lower v2-value, suggests the possibility of model overﬁt. A fol-
low-up analysis of a second-order factor model that took account
of the high inter-factor correlations resulted in Heywood cases,
suggesting that the second-order common factor is mis-speciﬁed.
Given the potential of model redundancy and factor multicolline-
arity, the three-factor structure of the PSQI was not supported.
The original one-factor model proposed by Buysse et al. [5] pro-
vided a poor model ﬁt to the data at Times 1 and 2. However, the
Table 2
Goodness-of-ﬁt indices for the factor models of PSQI.
Time Model v2 df CFI TLI RMSEA SRMR BIC
T1 1-factor 102.0* 14 0.771 0.657 0.179 0.077 3184.5
Revised 1-factor 21.4 13 0.978 0.965 0.057 0.042 3117.3
2-factor 21.4 13 0.978 0.965 0.057 0.042 3117.3
3-factor 12.6 11 0.996 0.992 0.027 0.031 3117.8
T2 1-factor 121.5* 14 0.702 0.553 0.204 0.099 3048.4
Revised 1-factor 20.1 13 0.980 0.968 0.055 0.040 2969.2
2-factor 20.1 13 0.980 0.968 0.055 0.040 2969.2
3-factor 12.2 11 0.997 0.994 0.024 0.030 2971.0
PSQI, Pittsburgh Sleep Quality Index; CFI, comparative ﬁt index; TLI, Tucker–Lewis index; RMSEA, root mean square error of approximation; SRMR, standardized root mean
square residual; BIC, Bayesian information criterion.
The revised 1-factor model added a residual covariance for sleep duration and habitual sleep efﬁciency.
* P < 0.05.
Fig. 1. The revised one-factor model of the Pittsburgh Sleep Quality Index with an
indicator-speciﬁc effect between sleep duration and habitual sleep efﬁciency. Circle
represents the latent variable; squares represent the seven components (from the
top: subjective sleep quality, sleep latency, sleep duration, habitual sleep efﬁciency,
sleep disturbances, sleep medication, and daytime dysfunction).
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a strong correlation in Time 1 (r = 0.76) and Time 2 (r = 0.78)
compared to other intercomponent correlations (r = 0.14–0.53).
This correlation pattern is consistent with the correlation matrix
of previous studies [6,10,12] where the two components showed
a similarly strong correlation (r = 0.69–0.76). As both components
were derived from the same item on the number of actual hours
slept, it is justiﬁable to take the indicator-speciﬁc effect into
account to enable a proper analysis of the factor structure. In thisTable 3
Correlations between PSQI factor scores and validating measures.
Variables Time 1 PSQI
Global score Sleep quality Sleep efﬁ
Anxiety 0.50* 0.55* 0.30*
Depression 0.34* 0.38* 0.18
Fatigue 0.34* 0.41* 0.13
Pain severity 0.31* 0.36* 0.16
Pain interference 0.45* 0.50* 0.26*
Quality of life 0.54* 0.58* 0.32*
PSQI, Pittsburgh Sleep Quality Index.
Values represent Pearson correlation coefﬁcients.
* P < 0.05 with Bonferroni correction for multiple comparisons.case, the standard CFA model with uncorrelated residual variables
was too restrictive. Given the much-improved model ﬁt for the
revised one-factor model, it is credible that the omission of the
indicator-speciﬁc covariance between the two overlapping compo-
nents contributed to the poor model ﬁt in the original one-factor
model. In future factor analysis of the PSQI, researchers should ac-
count for the indicator-speciﬁc effect between sleep duration and
habitual sleep efﬁciency.
Despite the overall acceptable ﬁt of the revised one-factor
model, the sleep medication indicator showed the lowest mean
and a low factor loading (k = 0.36 and 0.35 at Time 1 and 2,
respectively). This ﬁnding, which is compatible with results of
previous studies [6,12,14], reﬂects an avoidance of pharmacolog-
ical interventions in sleep problems due to side-effects or the
availability of behavioural interventions. Future studies should
elucidate the role of this component in assessing sleep distur-
bances in other sampling contexts.
The revised one-factor model and the two-factor model were
statistically equivalent. The latter provided exactly the same model
ﬁt and was indistinguishable from the former on a statistical basis.
We attempted to differentiate the twomodels on a practical basis by
examining the convergent validity of the PSQI scores of the two
models. As expected, the PSQI global scorewasmoderately and pos-
itively associated with anxiety, depression, pain, fatigue, and
reduced quality of life. Although comparable correlations were
found for the sleep quality factor, the sleep efﬁciency factor was
weakly or not signiﬁcantly associated with cancer-related psycho-
pathological states. That the PSQI global score was at least as good
as the two PQSI factor scores at predicting the psychopathological
states appears to imply that the two-factor PSQI scoring model
has little incremental predictive value over the PSQI global score.
Given the practical complexities of scoring and interpreting two
PSQI factor scores, the clinical utility of the two-factor model seems
dubious.
There are several limitations to this study. First, its results were
generated using an exclusive sample of breast cancer patients.
Although the revised one-factor model ﬁtted the data well andTime 2 PSQI
ciency Global score Sleep quality Sleep efﬁciency
0.53* 0.58* 0.29*
0.50* 0.50* 0.32*
0.45* 0.53* 0.20
0.35* 0.40* 0.17
0.49* 0.53* 0.26*
0.57* 0.59* 0.34*
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generalize to other populations. Future studies should attempt to
replicate the current ﬁndings and further examine the clinical util-
ity of the two-factor model in identifying sleep dysfunction in
other clinical samples and cultural contexts. Next, the convergent
validity of the PSQI might be inﬂated by the common method var-
iance that was present in self-report data. Future research should
incorporate structural interviews or clinical assessments as alter-
native assessment methods of sleep dysfunction.
In conclusion, this study is the ﬁrst to account for the indicator-
speciﬁc effect between sleep duration and habitual sleep efﬁciency
in the evaluation of the factor structure of the PSQI. The present
study demonstrated an adequate ﬁt for the one-factor structure for
the PSQI. The PSQI was found to be a precise and psychometrically
valid instrument that allows a straightforward global scoring for
screening of sleep dysfunction in cancer patients. It is recommended
that researchers and clinicians continue to use the PSQI global score
rather than the two-factor scoring system to identify clinically sig-
niﬁcant sleep disturbance.
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